Loading...
Loading...
- BioMarin Pharmaceutical Inc's BMRN Q2 sales reached $533.8 million, up 6% Y/Y, beating the consensus of $521.47 million.
- BioMarin said the increase was achieved "despite continued erosion of the U.S. Kuvan market." Total revenues grew 13% Y/Y, excluding Kuvan.
- The company reported EPS of $0.15 compared to $0.07 a year ago, beating the consensus of $0.11.
- Voxzogo for achondroplasia (dwarfism) reported sales of $34.4 million.
- An estimated 446 children were being treated with commercial Voxzogo globally, compared to 284 children in Q1 FY22.
- During the quarter, marketing authorization for Voxzogo was approved in Japan and Australia, with commercial sales anticipated in these markets to begin in Q3 of 2022.
- Guidance: BioMarin has upped its FY22 Voxzogo sales forecast to $130-$160 million, from $100 - $125 million expected earlier.
- The company expects FY revenues of $2.06-$2.16 billion, up from the previous guidance of $2.05 - $2.15 billion.
- BioMarin expects that Roctavian (valoctocogene roxaparvovec) for severe hemophilia A will be approved in Europe in Q3, and FDA resubmission is planned for September.
- Price Action: BMRN shares closed 0.96% lower at $87.55 during after-hours trading on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in